Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock

$15.10

0.27% yesterday

NYSE, Jun 27, 10:10 pm CET

ISIN

US8740602052

Symbol

TAK

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock price

$15.10

-3.01 16.62% 5Y

NYSE, Closing price Fri, Jun 27 2025

+0.04 0.27%

ISIN

US8740602052

Symbol

TAK

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$47.7b

Enterprise Value

$76.1b

Net debt

$28.4b

Cash

$2.8b

Shares outstanding

1.6b

Valuation (TTM | estimate)

P/E

32.13 | 14.74

P/S

1.51 | 1.49

EV/Sales

2.40 | 2.38

EV/FCF

15.53

P/B

0.50

Dividends

DPS

$0.67

Yield 1Y | 5Y

4.40% | 4.52%

Growth 1Y | 5Y

8.80% | -4.34%

Payout 1Y | 3Y

141.51% | 76.33%

Increased

1 Year

Financials (TTM | estimate)

Revenue

$31.7b | $32.0b

EBITDA

$6.6b | $8.4b

EBIT

$2.4b

Net Income

$746.1m | $1.6b

Free Cash Flow

$4.9b

Growth (TTM | estimate)

Revenue

7.45% | 1.01%

EBITDA

4.05% | 23.93%

EBIT

-14.05%

Net Income

-25.08% | 116.11%

Free Cash Flow

201.06%

Margin (TTM | estimate)

Gross

65.51%

EBITDA

20.90% | 26.40%

EBIT

7.48%

Net

2.36% | 5.04%

Free Cash Flow

15.48%

EPS

$0.47

FCF per Share

$3.12

Short interest

0.21%

Employees

49.28k

Rev per Employee

$640.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

??

21 Analysts have issued a Takeda Pharmaceutical Co. Ltd. Sponsored ADR forecast:

12x Buy

57%

9x Hold

43%

More details on Analyst Estimates Including Price Targets

21 Analysts have issued a Takeda Pharmaceutical Co. Ltd. Sponsored ADR forecast:

Buy

57%

Hold

43%

Analyst Estimates with Stock Price Targets

Financial data from Takeda Pharmaceutical Co. Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	31,672 31,672	7% 7% 100%
- Direct Costs	10,924 10,924	11% 11% 34%
Gross Profit	20,748 20,748	6% 6% 66%
- Selling and Administrative Expenses	7,637 7,637	5% 5% 24%
- Research and Development Expense	5,048 5,048	0% 0% 16%
EBITDA	6,618 6,618	4% 4% 21%
- Depreciation and Amortization	4,250 4,250	18% 18% 13%
EBIT (Operating Income) EBIT	2,368 2,368	14% 14% 7%
Net Profit	746 746	25% 25% 2%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock News

Neutral

Business Wire

●

3 days ago

Takeda Announces New Assignments of Directors

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th Annual Meeting of Shareholders, held in Osaka today. Takeda's Board of Directors has 11 members serving as external directors out of a total of 14 members, helping to ensure transparency and objectivity. An e...

Neutral

Business Wire

●

25 days ago

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) – a chemotherapy regimen – in adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma. The decisi...

Neutral

Business Wire

●

27 days ago

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. The data will be presented as a...

More Takeda Pharmaceutical Co. Ltd. Sponsored ADR News

Company Profile

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Head office	Japan
CEO	Christophe Weber
Employees	49,281
Founded	1781
Website	www.takeda.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now